BRPI0908268A2 - compostos do inibidor de raf e seus métodos de uso - Google Patents
compostos do inibidor de raf e seus métodos de usoInfo
- Publication number
- BRPI0908268A2 BRPI0908268A2 BRPI0908268A BRPI0908268A BRPI0908268A2 BR PI0908268 A2 BRPI0908268 A2 BR PI0908268A2 BR PI0908268 A BRPI0908268 A BR PI0908268A BR PI0908268 A BRPI0908268 A BR PI0908268A BR PI0908268 A2 BRPI0908268 A2 BR PI0908268A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- inhibitor compounds
- raf inhibitor
- raf
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3281308P | 2008-02-29 | 2008-02-29 | |
| PCT/US2009/035381 WO2009111279A1 (en) | 2008-02-29 | 2009-02-27 | Pyrazole [3, 4-b] pyridine raf inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0908268A2 true BRPI0908268A2 (pt) | 2018-10-30 |
Family
ID=40677552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908268A BRPI0908268A2 (pt) | 2008-02-29 | 2009-02-27 | compostos do inibidor de raf e seus métodos de uso |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8394795B2 (pt) |
| EP (1) | EP2265610B1 (pt) |
| JP (1) | JP2011513331A (pt) |
| KR (1) | KR20100117686A (pt) |
| CN (1) | CN102149712A (pt) |
| AR (1) | AR072657A1 (pt) |
| AU (1) | AU2009222144A1 (pt) |
| BR (1) | BRPI0908268A2 (pt) |
| CA (1) | CA2716952A1 (pt) |
| CL (1) | CL2009000448A1 (pt) |
| CR (1) | CR11690A (pt) |
| EC (1) | ECSP10010507A (pt) |
| ES (1) | ES2400202T3 (pt) |
| IL (1) | IL207845A0 (pt) |
| MA (1) | MA32272B1 (pt) |
| MX (1) | MX2010009411A (pt) |
| PE (1) | PE20091623A1 (pt) |
| TW (1) | TW200940539A (pt) |
| WO (1) | WO2009111279A1 (pt) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA2711782C (en) | 2008-01-09 | 2017-01-03 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| EP2265574A1 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| HUE027598T2 (en) | 2009-04-03 | 2016-10-28 | Hoffmann La Roche | Propane-1-sulfonic acid {3- [5- (4-chlorophenyl) -1H-pyrrolo [2,3-B] pyridine-3-carbonyl] -2,4-difluorophenyl} amide compositions and their uses |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| SG176885A1 (en) * | 2009-08-03 | 2012-01-30 | Acraf | Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates |
| SG178899A1 (en) * | 2009-08-28 | 2012-04-27 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
| CA2772316A1 (en) * | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase |
| ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
| WO2012094451A1 (en) | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| MA34948B1 (fr) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | Composes et procedes de modulation de kinase, et leurs indications |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2013043715A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| CN102491974B (zh) | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| WO2013127268A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
| WO2013169864A2 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JP6335169B2 (ja) | 2012-08-17 | 2018-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法 |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
| US9522876B2 (en) * | 2013-03-15 | 2016-12-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| RU2015143437A (ru) | 2013-03-15 | 2017-04-27 | Дженентек, Инк. | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака |
| AU2014274093B2 (en) | 2013-05-30 | 2018-11-08 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| PE20160125A1 (es) * | 2013-07-08 | 2016-03-17 | Bayer Pharma AG | Pirazolpiridinas sustituidas |
| CN105683182A (zh) | 2013-08-30 | 2016-06-15 | 埃姆比特生物科学公司 | 联芳基乙酰胺化合物及其使用方法 |
| EP3154589A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| MX2017000546A (es) | 2014-07-15 | 2017-03-08 | Genentech Inc | Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek. |
| WO2016038582A1 (en) * | 2014-09-12 | 2016-03-17 | Novartis Ag | Compounds and compositions as raf kinase inhibitors |
| PL3377107T3 (pl) | 2015-11-19 | 2020-12-14 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu przy użyciu inhibitorów b-raf i inhibitorów immunologicznego punktu kontrolnego |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| JP7359772B2 (ja) * | 2017-11-01 | 2023-10-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 検体検出方法 |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110627691B (zh) * | 2019-08-20 | 2022-03-25 | 中船(邯郸)派瑞特种气体股份有限公司 | 一种制备n-苯基-双(全氟烷基磺酰)亚胺的方法 |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6121M (pt) * | 1966-01-12 | 1968-06-17 | ||
| NZ186175A (en) * | 1977-01-27 | 1980-03-05 | Shionogi & Co | Meta-sulphonamidobenzamide derivatives |
| US5800711A (en) * | 1996-10-18 | 1998-09-01 | Mdv Technologies, Inc. | Process for the fractionation of polyoxyalkylene block copolymers |
| DE69837282T2 (de) | 1997-12-13 | 2007-11-08 | Bristol-Myers Squibb Co. | VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER |
| SK285371B6 (sk) | 1997-12-22 | 2006-12-07 | Bayer Corporation | Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom |
| HUP0101704A3 (en) | 1997-12-22 | 2002-12-28 | Bayer Corp Pittsburgh | Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them |
| EP1049664B1 (en) | 1997-12-22 | 2005-03-16 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| CA2359244C (en) * | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) * | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7351834B1 (en) * | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6761824B2 (en) * | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
| US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20030207914A1 (en) * | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| US20020192289A1 (en) * | 2001-06-18 | 2002-12-19 | Ji Zheng | Polymer gel for cancer treatment |
| GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| ATE447404T1 (de) * | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| KR101425385B1 (ko) * | 2003-03-24 | 2014-07-31 | 플루로메드, 인코포레이티드 | 역성 열감응 중합체를 사용하는 일시적인 색전화 |
| PL1635835T3 (pl) * | 2003-06-13 | 2010-06-30 | Novartis Ag | Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF |
| EP1643991B1 (en) * | 2003-07-11 | 2014-03-12 | Merck Patent GmbH | Benzimidazole carboxamides as raf kinase inhibitors |
| US7691886B2 (en) * | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
| KR101415503B1 (ko) * | 2003-07-17 | 2014-07-04 | 플렉시콘, 인코퍼레이티드 | Ｐｐａｒ 활성 화합물 |
| DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| JP4758349B2 (ja) * | 2003-10-08 | 2011-08-24 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US7691866B2 (en) * | 2003-10-16 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase |
| JP4755991B2 (ja) * | 2003-10-16 | 2011-08-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用 |
| PL1696920T3 (pl) * | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Związki i sposoby opracowywania modulatorów Ret |
| DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| MX2007002434A (es) * | 2004-08-31 | 2007-05-04 | Astrazeneca Ab | Derivados de quinazolinona y su uso como inhibidores de b-raf. |
| WO2006024836A1 (en) * | 2004-09-01 | 2006-03-09 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| EP1799679B1 (de) | 2004-10-13 | 2008-01-23 | Merck Patent GmbH | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
| CA2584170C (en) | 2004-10-13 | 2013-08-20 | Wolfgang Staehle | Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases |
| JP2008516939A (ja) * | 2004-10-15 | 2008-05-22 | アストラゼネカ アクチボラグ | 化学化合物 |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| MX2007007574A (es) | 2004-12-22 | 2007-07-24 | Astrazeneca Ab | Derivados de piridina-carboxamida para uso como agentes anticancerosos. |
| WO2006071940A2 (en) * | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| CN101087787A (zh) | 2004-12-23 | 2007-12-12 | 霍夫曼-拉罗奇有限公司 | 苯甲酰胺衍生物，它们的制备及作为药剂的应用 |
| AU2006208834A1 (en) * | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
| JP2008528585A (ja) * | 2005-01-26 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| CA2601766A1 (en) * | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| WO2006124780A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase |
| WO2006124731A2 (en) | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| DE602006019088D1 (de) * | 2005-05-13 | 2011-02-03 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinase-hemmer |
| CA2608733A1 (en) * | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| RU2007147382A (ru) * | 2005-05-20 | 2009-06-27 | Эррэй Биофарма Инк. (Us) | Соединения, являющиеся ингибиторами raf, и способы их применения |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| EP1919910B1 (en) | 2005-07-29 | 2011-02-23 | F. Hoffmann-La Roche AG | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents |
| AU2006279992A1 (en) * | 2005-08-09 | 2007-02-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US20070049603A1 (en) * | 2005-09-01 | 2007-03-01 | Greg Miknis | Raf inhibitor compounds and methods of use thereof |
| JP4908511B2 (ja) * | 2005-09-15 | 2012-04-04 | エフ．ホフマン−ラ ロシュ アーゲー | ４−アミノ−チエノ［３，２−ｃ］ピリジン−７−カルボン酸誘導体 |
| EP1951728A4 (en) * | 2005-11-04 | 2011-04-20 | Glaxosmithkline Llc | THIENOPYRIDINES AS INHIBITORS OF B-RAF KINASE |
| AU2006322094A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| RU2442778C9 (ru) * | 2005-12-13 | 2012-08-10 | Шеринг Корпорейшн | Новые соединения, действующие как ингибиторы erk |
| JP2009520784A (ja) * | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | キナゾリン誘導体、その製造方法および抗癌剤としてのその使用 |
| WO2007076460A2 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
| WO2007076474A1 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| EP2007736A1 (en) * | 2006-04-05 | 2008-12-31 | AstraZeneca AB | Substituted quinazolines with anti-cancer activity |
| JP2009532450A (ja) * | 2006-04-05 | 2009-09-10 | アストラゼネカ アクチボラグ | 化合物 |
| CN101421253A (zh) * | 2006-04-18 | 2009-04-29 | 阿斯利康(瑞典)有限公司 | 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物 |
| US20070224169A1 (en) * | 2006-07-18 | 2007-09-27 | Sliwa John W Jr | Selectively switched gels for surgery, therapy and maintenance |
| US8067599B2 (en) * | 2006-09-06 | 2011-11-29 | Hoffman-La Roche Inc. | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| MX2009003456A (es) * | 2006-10-02 | 2009-04-14 | Irm Llc | Compuestos y composiciones como inhibidores de proteina cinasa. |
| WO2008044688A1 (en) | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2008073938A2 (en) * | 2006-12-11 | 2008-06-19 | Pluromed, Inc. | Perfusive organ hemostasis |
| WO2008080015A2 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| WO2008112695A2 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| WO2008124393A1 (en) | 2007-04-04 | 2008-10-16 | Irm Llc | Benzothiazole derivatives and their use as protein kinase inhibitors |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| AU2008266290A1 (en) * | 2007-06-15 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| BRPI0813216A2 (pt) * | 2007-06-21 | 2014-12-23 | Irm Llc | Inibidores de proteínas cinases e métodos para usá-los. |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP5270553B2 (ja) * | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP5350247B2 (ja) * | 2007-08-29 | 2013-11-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2265574A1 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| PL2947072T3 (pl) * | 2008-03-17 | 2017-05-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| US8158636B2 (en) * | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8119637B2 (en) * | 2008-06-10 | 2012-02-21 | Plexxikon Inc. | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor |
| US8110576B2 (en) * | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
-
2009
- 2009-02-27 EP EP09718306A patent/EP2265610B1/en active Active
- 2009-02-27 CN CN2009801155134A patent/CN102149712A/zh active Pending
- 2009-02-27 ES ES09718306T patent/ES2400202T3/es active Active
- 2009-02-27 BR BRPI0908268A patent/BRPI0908268A2/pt not_active IP Right Cessation
- 2009-02-27 CA CA2716952A patent/CA2716952A1/en not_active Abandoned
- 2009-02-27 AU AU2009222144A patent/AU2009222144A1/en not_active Abandoned
- 2009-02-27 MX MX2010009411A patent/MX2010009411A/es not_active Application Discontinuation
- 2009-02-27 AR ARP090100688A patent/AR072657A1/es unknown
- 2009-02-27 KR KR1020107021611A patent/KR20100117686A/ko not_active Withdrawn
- 2009-02-27 PE PE2009000310A patent/PE20091623A1/es not_active Application Discontinuation
- 2009-02-27 US US12/920,050 patent/US8394795B2/en not_active Expired - Fee Related
- 2009-02-27 JP JP2010548886A patent/JP2011513331A/ja not_active Withdrawn
- 2009-02-27 WO PCT/US2009/035381 patent/WO2009111279A1/en not_active Ceased
- 2009-02-27 CL CL2009000448A patent/CL2009000448A1/es unknown
- 2009-02-27 TW TW098106512A patent/TW200940539A/zh unknown
-
2010
- 2010-08-29 IL IL207845A patent/IL207845A0/en unknown
- 2010-09-24 MA MA33203A patent/MA32272B1/fr unknown
- 2010-09-27 CR CR11690A patent/CR11690A/es unknown
- 2010-09-28 EC EC2010010507A patent/ECSP10010507A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100117686A (ko) | 2010-11-03 |
| EP2265610A1 (en) | 2010-12-29 |
| ES2400202T3 (es) | 2013-04-08 |
| MA32272B1 (fr) | 2011-05-02 |
| AR072657A1 (es) | 2010-09-15 |
| JP2011513331A (ja) | 2011-04-28 |
| CN102149712A (zh) | 2011-08-10 |
| CA2716952A1 (en) | 2009-09-11 |
| US8394795B2 (en) | 2013-03-12 |
| WO2009111279A1 (en) | 2009-09-11 |
| US20110092479A1 (en) | 2011-04-21 |
| EP2265610B1 (en) | 2012-12-12 |
| CL2009000448A1 (es) | 2009-11-27 |
| CR11690A (es) | 2010-11-02 |
| PE20091623A1 (es) | 2009-11-19 |
| TW200940539A (en) | 2009-10-01 |
| MX2010009411A (es) | 2010-11-30 |
| AU2009222144A1 (en) | 2009-09-11 |
| ECSP10010507A (es) | 2010-10-30 |
| IL207845A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915231A2 (pt) | compostos inibidores de quinase e métodos de uso | |
| BRPI0921862A2 (pt) | inibidores de raf e seus usos | |
| CY2019010I2 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
| BRPI0910346A2 (pt) | compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso | |
| BRPI1011384A2 (pt) | pro-proteinas e seus metodos de uso | |
| SMT201600278B (it) | Inibitori della benzossazolo chinasi e metodi d'uso | |
| SMT201500218B (it) | Composti aril-fenil-solfonammido-cicloalchile e loro uso | |
| IL207843A0 (en) | Raf inhibitor compounds and methods of use thereof | |
| HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
| BRPI0916269A2 (pt) | dispositivo de modificação de tecido e seu método de uso | |
| CR20130360A (es) | Compuesto heterocíclico y su uso | |
| BRPI0913086A2 (pt) | Composições antimicrobianas e métodos de uso | |
| BRPI0920263A2 (pt) | composto, uso do composto, composição, e, método | |
| SMT201500206B (it) | Composti spiro-ossindolici e loro uso come agenti terapeutici | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
| BRPI0916769A2 (pt) | derivados de benzilbenzeno deuterados e métodos de uso | |
| BRPI0918693A2 (pt) | dispositivos para amostragem e métodos para concentração de microorganismos | |
| HRP20190016T1 (hr) | Heterociklički spojevi i njihova upotreba | |
| BRPI0817881A2 (pt) | Compostos orgânicos e seus usos | |
| BRPI1014544A2 (pt) | anticorpors anti-il-17f e metodos de uso dos mesmos | |
| BRPI1011129A2 (pt) | métodos e compostos inibidores de janus cinase | |
| BRPI0922344A2 (pt) | inibidores de tfpi e métodos de uso | |
| PL3812360T3 (pl) | Związki monochlorotrifluoropropenu oraz kompozycje i sposoby ich zastosowania | |
| PL2152256T3 (pl) | Związki aktywujące telomerazę i sposoby ich zastosowania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |